SpringWorks Therapeutics Inc’s recent filing unveils that its Director DANIEL LYNCH acquired Company’s shares for reported $2.81 million on Feb 14 ’25. In the deal valued at $58.59 per share,48,000 shares were bought.
Then, Pichl Daniel sold 29,750 shares, generating $1,617,329 in total proceeds. Upon selling the shares at $54.36, the Chief People Officer now owns 50,762 shares.
Before that, LYNCH DANIEL sold 175,000 shares. SpringWorks Therapeutics Inc shares valued at $9,530,351 were divested by the Director at a price of $54.46 per share. As a result of the transaction, LYNCH DANIEL now holds 130,944 shares, worth roughly $7.37 million.
Evercore ISI initiated its SpringWorks Therapeutics Inc [SWTX] rating to an Outperform in a research note published on November 20, 2024; the price target was $60. A number of analysts have revised their coverage, including Guggenheim’s analysts, who began to cover the stock in early February with a ‘”a Buy”‘ rating. BofA Securities began covering SWTX with “Buy” recommendation on December 01, 2022. H.C. Wainwright maintained its rating on January 19, 2021. It rated SWTX as “a Buy”.
Price Performance Review of SWTX
On Tuesday, SpringWorks Therapeutics Inc [NASDAQ:SWTX] saw its stock fall -1.97% to $56.30. Over the last five days, the stock has gained 4.26%. SpringWorks Therapeutics Inc shares have risen nearly 55.83% since the year began. Nevertheless, the stocks have risen 21.00% over the past one year. While a 52-week high of $60.00 was reached on 02/14/25, a 52-week low of $28.21 was recorded on 01/15/25. SMA at 50 days reached $40.03, while 200 days put it at $37.89.
Levels Of Support And Resistance For SWTX Stock
The 24-hour chart illustrates a support level at 55.21, which if violated will result in even more drops to 54.11. On the upside, there is a resistance level at 57.20. A further resistance level may holdings at 58.09. The Relative Strength Index (RSI) on the 14-day chart is 72.44, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 11.24, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 15.04%. Stochastics %K at 88.02% indicates the stock is a selling.
The most recent change occurred on October 29, 2020 when H.C. Wainwright resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $73.
